GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art.

Although semaglutide is associated with a decline in eGFR in the first 12–16 weeks of treatment and then stabilized, the overall difference compared with other antidiabetic drugs and to placebo over the entire observation period was statistically insignificant; furthermore, UACR values showed a decreasing trend in the group of patients treated with semaglutide.

also in 47,180 other papers